Lynparza™ approved in the EU as first-in-class treatment for advanced BRCA-mutated ovarian cancer
AstraZeneca announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 18, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Oncology BRCA-mutated Latest News olaparib ovarian cancer platinum-based chemotherapy Source Type: news
Patients with active ulcerative colitis gain access to biologic therapies on the NHS
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. (1) SIMPONI is recommended only if MSD provides the 100mg dose at the same cost as the 50mg dose, as ...
Source: Pharmacy Europe - December 12, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Legislation & regulation Gastroenterology Patient care humira Latest News remicade Simponi ulcerative colitis Source Type: news
Takeda announces 4-year survival data from ADCETRIS® pivotal trial at ASH annual meeting
Takeda UK announced 4-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 10, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Other conferences & symposia Oncology Patient care ALCL antibody-drug conjugate brentuximab vedotin Hodgkin lymphoma Latest News Source Type: news
Takeda reports Phase III AETHERA clinical trial data from ADCETRIS® at ASH annual meeting
Takeda UK Ltd reports data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 9, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology Oncology antibody-drug conjugate autologous stem cell transplant brentuximab vedotin Hodgkin lymphoma Latest News systemic anaplastic large cell lymph Source Type: news
UKCPA Introduction to Pharmaceutical Care Course 2015
The UKCPA Introduction to Pharmaceutical Care has been designed to help participants extend their clinical knowledge and to develop the skills that underpin the delivery of pharmaceutical care. This course will be invaluable to all those who wish to provide patient-focussed pharmaceutical care in either community or hospital practice. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 8, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Patient care clinical practice Introduction to Pharmaceutical Care Course medication review My Practice risk management ukcpa workshops Source Type: news
Bayer submits marketing authorisation application for haemophilia A product
Bayer HealthCare submitted an application for marketing authorisation to the European Medicines Agency (EMA) for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, for the treatment of haemophilia A in children and adults. BAY 81-8973 is a full-length recombinant Factor VIII that has demonstrated clinical evidence of efficacy when used for prophylaxis 2 or 3 times per week, with typical dosages. (1) Bayer plans to file BAY 81-8973 for approval in other countries in the coming months. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 5, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology Patient care BAY 81-8973 blood coagulation proteins haemophilia a Latest News LEOPOLD II trial low-dose prophylaxis regimen recombinant Factor VIII Source Type: news
A global call for awareness of psoriasis as a disability
On the International Day of Persons with Disabilities, the International Federation of Psoriasis Associations, IFPA, launches an issue brief highlighting the physical and social barriers that people with psoriasis and psoriatic arthritis face, calling governments around the world to action. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 3, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Dermatology Rheumatology IFPA Latest News national disability programs physical and social barriers psoriasis psoriatic arthritis Source Type: news
NICE reverses decision on access to new blood cancer drug
NHS patients in England and Wales with chronic lymphocytic leukaemia (CLL) could soon benefit from Gazyvaro, which has today been given the provisional green light by the National Institute for Health and Care Excellence (NICE). (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 3, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Oncology Patient care Policy & practice cll Gazyvaro Latest News nice progression free survival type II anti-CD20 monoclonal antibody Source Type: news
SC mAbs: remodelling traditional anticancer therapy
Subcutaneous monoclonal antibodies are replacing traditional intravenous biotherapeutics and this switch offers opportunities to remodel cancer services through the advantages that subcutaneous formulations confer (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Biological therapy in RA: cost-effectiveness
Rheumatoid arthritis is a chronic disease that can be treated with NSAIDs, traditional DMARDs or a combination of these and biological therapy, the cost-effectiveness of which are considered in this article (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
The management of chronic constipation
Treatment strategies for chronic constipation invoving dietary modification and laxatives often do not provide satisfactory results but newer agents, such as lubiprostone and prucalopride offer significant advances in the management of this prevalent condition (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Subcutaneous administration of rituximab
Given the shorter delivery time and lack of need for dedicated infusion facilities, subcutaneous formulations of rituximab could potentially improve convenience and quality of life for patients and provide cost savings to healthcare systems (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Medicines reconciliation on admission: further issues
In the final article of this short series, further issues surrounding medicines reconciliation (including surgical pre-operative assessment and Connecting Care) at North Bristol NHS Trust are discussed (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
The EU Sharps Directive and personnel safety
Legislation to protect healthcare professionals came into force in Europe
in 2013 and implementation is progressing but partial compliance is common
and a zero tolerance policy to sharps injuries is needed (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Antibiotic stewardship and EP: opportunities and dilemmas
Antibiotic stewardship and resistance are of international importance. Electronic prescribing systems offer some real opportunities to improve and monitor the use of antibiotics as well as presenting users with a few dilemmas (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 2, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
